Healthcare
Kenvue Rebounds After Tylenol Autism Claims Spark Market Jitters
Analysts cite lack of new scientific evidence as shares recover from record low Kenvue (KVUE) shares rose 6% on Tuesday,...
NeuroNOS Earns FDA Orphan Drug Designation for Glioblastoma Therapy
BA-101 aims to address urgent unmet needs in one of the deadliest brain cancers NeuroNOS, a subsidiary of Beyond Air...
Viking Therapeutics Shares Plunge After High Dropout Rate in Weight-Loss Pill Trial
Strong weight reduction overshadowed by concerns over side effects Viking Therapeutics (VKTX) shares plummeted nearly 45% on Tuesday after the...
Eli Lilly Strikes $1.3 Billion Deal with Superluminal Medicines to Advance AI-Driven Obesity Drug Development
Partnership leverages artificial intelligence to accelerate discovery of next-generation treatments for obesity and cardiometabolic diseases Eli Lilly (LLY) has entered...
Eli Lilly Posts Strong Q2 Earnings but GLP-1 Pill Disappointment Weighs on Stock
Zepbound and Mounjaro Drive U.S. Sales, Yet Orforglipron Trial Results Raise Investor Concerns Eli Lilly (LLY) delivered a solid second-quarter...
Daxor’s New Handheld Blood Volume Analyzer Gets FDA Green Light
Next-Gen BVA Device Promises Faster, More Accurate Fluid Management for Millions of Patients Daxor Corporation (DXR), a global leader in...
Hims & Hers Shares Dip Despite Strong Growth as Revenue Misses Forecast
Telehealth company maintains 2025 outlook, expands beyond GLP-1 offerings amid regulatory and partnership setbacks Hims & Hers Health (HIMS) stock...
ProMIS Neurosciences Soars 160% After FDA Fast Track Designation for Alzheimer’s Drug
PMN310 aims to deliver a safer, next-generation treatment by targeting toxic amyloid-beta in early-stage Alzheimer’s patients Shares of ProMIS Neurosciences...
Regencell Bioscience’s Stock Whipsaws Again Amid 17,000% Surge in 2025
Following a 38-to-1 stock split and explosive rally, the biotech firm's volatile trading persists despite a multi-year loss streak Regencell...
EXCLUSIVE: MIRA Pharmaceuticals’ Disruptive Path In Neurology And Metabolic Disorders
CEO Erez Aminov on Breakthrough Drug Candidates, Strategic Acquisitions, and the Vision Behind MIRA’s Innovation-Driven Pipeline MIRA Pharmaceuticals (NASDAQ: MIRA),...
